<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000543500">
  <TermName>anti-mesothelin monoclonal antibody MORAb-009</TermName>
  <TermPronunciation>(AN-tee-MEH-zoh-THEE-lin MAH-noh-KLOH-nul AN-tee-BAH-dee…)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of mesothelioma. Anti-mesothelin monoclonal antibody MORAb-009 binds to a protein called mesothelin, which is found on some cancer cells. Anti-mesothelin monoclonal antibody MORAb-009 may help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called amatuximab and MORAb-009.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000718280" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anti-mesothelin monoclonal antibody MORAb-009&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000718279" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;anticuerpo monoclonal MORAb-009 antimesotelina&quot;" language="es" id="_4"/>
  <SpanishTermName>anticuerpo monoclonal MORAb-009 antimesotelina</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del mesotelioma. El anticuerpo monoclonal MORAb-009 antimesotelina se une a una proteína llamada mesotelina, que se encuentra en algunas células cancerosas. El anticuerpo monoclonal MORAb-009 antimesotelina podría ayudar al sistema inmunitario a destruir células cancerosas. Es un tipo de anticuerpo monoclonal. También se llama amatuximab y MORAb-009.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2007-04-13</DateFirstPublished>
  <DateLastModified>2014-03-10</DateLastModified>
</GlossaryTerm>
